TMPRSS11D and neoplasm: Molecular pathways included but are not limited to cell cycle arrest and apoptosis, HAT inhibition, DNA methylation, histone acetylation, downregulation of oncogenic miRNAs, upregulation of tumor-suppressive miRNAs, inhibition of NF-kB, STAT 3, P13/Akt, COX-2, MAPK pathways, inhibition of epithelial-to-mesenchymal transition (EMT), and cancer stem cell targeting.